AstraZeneca v. Apotex: Promising Change in Patent Law

Price: $95.00

Member Price: $75.00

Add to Cart

Held on July 20, 2017

In a landmark ruling, the Supreme Court of Canada has rejected the “Promise Doctrine”, calling it “unsound”. The Court found that the promise of a patent is insufficient to determine “whether the utility requirement of s.2 of the Patent Act is met.”

How will the decision impact patent protection in Canada, will it have repercussions on innovation, will it change the way patent practitioners advise their clients? Do we have answers?

Join our experts as they discuss the implications of the ruling on patent law and patent practice in Canada.


Scott Beeser Aitken Klee LLP
Kristin Wall Norton Rose Fulbright Canada LLP


Jason Markwell Belmore Neidrauer LLP

Continuing Professional Development

This program is eligible for up to 1 Substantive Hour.

If you wish to receive CPD accreditation for this webinar please write to when you have completed viewing the recording. Please provide the CPD code as provided in the recording.


1 hr

Law Society of Upper Canada


Barreau du Québec


Law Society of British Columbia


Law Society of Saskatchewan


Law Society of Manitoba


Law Society of Alberta


New York CLE Board